A once-groundbreaking sickle cell disease drug — at the center of a $5.4 billion acquisition two years ago — is the subject ...

Investment analysts at Leerink Partnrs lifted their FY2025 earnings estimates for Pfizer in a report issued on Wednesday, ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

On Friday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $26.36 which represents a slight increase of $0.59 or 2.29% from the prior close of $25.77. The stock opened at $ and touched a ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

In a report released yesterday, Steve Scala from TD Cowen maintained a Hold rating on Pfizer (PFE – Research Report). The company’s shares ...

We recently published a list of the 10 Best Stocks to Buy and Hold For 3 Years. In this article, we are going to take a look ...

Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is ...

We recently published a list of the 8 Best Dividend Leaders to Buy According to Wall Street Analysts. In this article, we are ...

Based on a handful of valuation tools, we're witnessing one of the priciest stock markets in history. Statistically speaking, ...

During the three years that the share price fell, Pfizer's earnings per share (EPS) dropped by 40% each year. This fall in ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...